Group 1 - The Regional Comprehensive Economic Partnership (RCEP) has been effective since January 1, 2022, leading to a steady increase in the value of tariff reductions and benefits for enterprises in Beijing, with a cumulative import value of 15.38 billion and a tax reduction of 652 million [1] - By 2025, enterprises in Beijing are expected to enjoy a benefit value of 5.175 billion and a tax reduction of 237 million, indicating continued growth in trade benefits under RCEP [1] - Beijing Customs has signed a total of 109,400 certificates of origin for exports to RCEP countries, amounting to 56.157 billion, with 31,224 certificates and 14.831 billion expected in 2025 [1] Group 2 - Beijing Tongrentang Health Pharmaceutical Co., Ltd. has benefited from RCEP, with the import tariff on bird's nest from ASEAN countries reduced from 25% to zero, lowering procurement costs and enhancing product competitiveness [2] - The approved exporter system under RCEP allows qualified enterprises to issue their own origin declarations, providing the same validity as traditional certificates without the need for visa, thus streamlining the export process [2] - Beijing Customs aims to enhance services and optimize regulations based on feedback from enterprises, collaborating with local governments and industry associations to promote the application of RCEP rules [2]

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.39% on January 21, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - *ST Changyao: Closed at 0.64, up 20.75% with a trading volume of 519,700 shares and a turnover of 32.17 million yuan [1] - Tianmu Pharmaceutical: Closed at 22.29, up 8.47% with a trading volume of 128,100 shares and a turnover of 282 million yuan [1] - Wanbangde: Closed at 17.82, up 5.13% with a trading volume of 196,800 shares and a turnover of 34.2 million yuan [1] - Conversely, Zhongsheng Pharmaceutical saw a decline of 4.26%, closing at 21.12 with a trading volume of 685,100 shares and a turnover of 144.9 million yuan [2] Capital Flow - The traditional medicine sector experienced a net outflow of 281 million yuan from major funds, while retail investors saw a net inflow of 78.63 million yuan [2] - Major funds showed significant net inflows in stocks such as Yunnan Baiyao, which had a net inflow of 78.68 million yuan, and Wanbangde with a net inflow of 22.17 million yuan [3]

Core Insights - The article emphasizes the evolution of consumer expectations from basic safety compliance to a demand for quality certainty and efficacy in food products, highlighting the importance of trust in brand value [1][4][41] Group 1: Traceability in Food Industry - The search index for "food traceability" keywords increased by 157.39% year-on-year in the first half of 2025, indicating a growing consumer interest in product origins and processing [2] - Companies like Nongfu Spring are pioneers in traceability practices, transforming their water source into a symbol of brand trust [2] - Major food brands, including McDonald's and KFC, have initiated traceability journeys, but face challenges in differentiating their offerings in a crowded market [2][4] Group 2: Evolution of Traceability - Traceability marketing has shifted from merely ensuring safety compliance to establishing quality certainty and efficacy stability, driven by consumer health demands and technological advancements [4][5] - The traceability system has evolved from simple information recording to a standardized carrier of product value, integrating into brand building, product innovation, and user delivery [4][5] Group 3: Role of Technology - The traceability system in functional foods is advancing from basic safety assurance to a standardized and refined approach, similar to the beauty industry’s control over active ingredients [9] - Brands are increasingly using digital traceability to provide comprehensive production data, ensuring that active ingredients remain effective through industrial processing [14][15] Group 4: Consumer Engagement - Over 60% of global consumers are willing to pay a premium for brands that transparently disclose ingredient sources and production details, indicating a strong demand for transparency [8] - The trend is particularly pronounced in functional foods, where traceability is becoming a key component of building technical barriers [8][9] Group 5: Supply Chain Management - The ultimate value of traceability lies in the ability to deepen and control the supply chain, transitioning from mere production capabilities to sustainable selling [39][40] - Companies are moving from passive procurement to active supply chain management, enhancing their ability to respond to consumer demands quickly [40] Group 6: Traditional Chinese Medicine and Modernization - The market for "medicinal food" is projected to exceed 500 billion yuan by 2025, driven by consumer demand for standardized and verified products [25][26] - Brands are constructing comprehensive traceability systems to address issues of origin confusion and safety in traditional Chinese medicine [27][29] Group 7: Geographic Branding - Geographic indicators are being transformed into tangible brand assets through traceability, allowing consumers to verify the authenticity and quality of regional products [37][38] - Successful case studies, such as the sales of birch juice from Yichun, demonstrate the effectiveness of deep traceability in building consumer trust [38]

Group 1 - The company has completed the registration process for a name change from "Jiangzhong Pharmaceutical" to "China Resources Jiangzhong," with the stock code remaining 600750 [1][3] - The name change aims to strengthen brand synergy with China Resources Group and enhance brand recognition and market influence [3][4] - This change marks the full integration of Jiangzhong Pharmaceutical into the China Resources brand system after six years of restructuring since China Resources Group became the controlling shareholder in 2019 [3][4] Group 2 - Jiangzhong Pharmaceutical's revenue for the first three quarters of 2025 was 2.933 billion yuan, a year-on-year decline of 6.28%, with the third quarter showing a more significant drop of 7.59% [4] - The core over-the-counter (OTC) product, Jianwei Jianshi Pian, has seen declining sales, with a 10.65% drop in revenue in the third quarter of 2025 [4][6] - The company is facing intense competition in the OTC market, with numerous similar products available, leading to a significant increase in marketing expenses, which accounted for nearly one-third of revenue [6][5] Group 3 - The company is focusing on developing its prescription drug segment as a potential second growth curve, with a revenue of 790 million yuan in 2024, down 3.5% year-on-year [5][6] - The company has outlined three strategic goals: strengthening OTC products, developing health consumer goods, and expanding the prescription drug segment [6]

Core Insights - The 2025 consumer market is expected to develop healthily, with measures to boost consumption meeting diverse consumer needs and improving the consumption environment [1] - The 20th National Congress of the Communist Party of China emphasizes the importance of boosting consumption as part of the 14th Five-Year Plan [1] - The "Three-Year Action Plan to Optimize the Consumption Environment" aims to address consumer pain points and enhance consumer rights protection [2] Group 1: Policy and Regulatory Developments - The 20th National Congress approved the 14th Five-Year Plan, focusing on boosting consumption through various measures, including increasing public service spending and enhancing consumer capacity [1] - The "Three-Year Action Plan" outlines 19 key tasks to create a fair and safe consumption environment, including quality control and consumer rights protection initiatives [2] Group 2: Consumer Rights and Protection - The theme for 2025's Consumer Rights Year is "Building Satisfactory Consumption," aiming to enhance consumer experience and strengthen rights protection [2] - The Shanghai Consumer Rights Protection Committee exposed false advertising related to Antarctic krill oil, highlighting the need for accountability in consumer goods [3] Group 3: Emerging Issues in Consumption - The rise of private domain live streaming has led to issues such as false advertising and consumer rights challenges, prompting investigations and calls for regulation [4] - The investigation into the "Northeast Brothers" revealed fraudulent practices under the guise of supporting farmers, resulting in penalties and refunds for affected consumers [6] Group 4: Market Trends and Innovations - New consumption scenarios are reshaping economic dynamics, with innovative urban developments and consumer demands driving growth [5] - The investigation into "Hong Kong Pharmacy" revealed deceptive branding practices, leading to regulatory actions against involved companies [7] Group 5: Technology and Consumer Awareness - The misuse of AI face-swapping technology has raised concerns about consumer deception and privacy violations, prompting discussions on regulatory frameworks [8] - Complaints regarding automatic payment systems have surged, leading to investigations into consumer rights and the need for clearer opt-out processes [9]

Core Viewpoint - A product named "Ginseng Bitter Melon Buckwheat Mulberry Leaf Tablets" is being marketed as a "sugar-lowering miracle drug" on various online platforms, particularly targeting elderly individuals with high blood sugar and diabetes, despite lacking scientific backing for its claims [1][4]. Group 1: Product Marketing and Claims - The product is heavily promoted on short video platforms, with influencers and AI hosts endorsing its benefits without clearly stating its intended use [1]. - Customer service representatives from various platforms claim that the product can help regulate blood sugar levels, but the actual product descriptions often avoid direct claims of medical efficacy [4][6]. - Many customer reviews suggest that users are treating the product as a substitute for diabetes medication, indicating a misunderstanding of its actual purpose [4]. Group 2: Regulatory and Safety Concerns - The product is classified as a food item rather than a health supplement or medication, which means it does not have the necessary regulatory approval for health claims [5]. - The marketing strategies employed by sellers often skirt around legal restrictions on advertising health benefits, leading to vague and misleading statements [6]. - Ingredients such as maltodextrin and glucose, which are present in the product, can actually raise blood sugar levels, contradicting the claims of being a "sugar-lowering" product [7][10]. Group 3: Expert Opinions and Scientific Evidence - Experts indicate that while some ingredients like ginseng and bitter melon may have potential benefits for blood sugar regulation, they are not effective in the concentrations found in these products [10][11]. - The low concentration of active ingredients raises questions about the product's efficacy, as the beneficial components are present in negligible amounts [10]. - It is emphasized that these products should not replace conventional diabetes treatments, and consumers should be cautious of misleading claims that could delay proper medical care [11].

Core Viewpoint - A product named "Ginseng Bitter Melon Buckwheat Mulberry Leaf Tablets" is being marketed as a "sugar-lowering miracle drug" on various online platforms, particularly targeting elderly individuals with high blood sugar and diabetes, despite lacking scientific backing for such claims [1][4][5]. Group 1: Product Marketing and Claims - The product is heavily promoted on short video platforms, with influencers and AI hosts endorsing its benefits without clearly stating its intended use [1][4]. - Customer service representatives from various platforms claim that the product can help regulate blood sugar levels, but these claims are often vague and avoid direct references to medical benefits [4][5]. - Many customer reviews suggest that users are treating the product as a substitute for diabetes medication, indicating a misunderstanding of its actual purpose [4][6]. Group 2: Regulatory and Safety Concerns - The product is classified as a food item rather than a health supplement or medication, which means it cannot legally claim to treat or prevent diseases [5][6]. - The ingredients listed in the product, such as glucose and maltodextrin, are known to raise blood sugar levels, contradicting its marketed benefits [6][8]. - Experts warn that while some ingredients may have potential health benefits, the product's formulation does not provide sufficient active ingredients to achieve any therapeutic effect [8][9]. Group 3: Expert Opinions - Experts emphasize that while certain ingredients like mulberry leaves and bitter melon may have some blood sugar-lowering properties, they should not replace conventional diabetes treatments [9]. - The low concentration of active ingredients in the product raises questions about its efficacy, with experts noting that the claims made by marketers could be misleading [8][9].

证券代码：600085 证券简称：同仁堂 公告编号：2026-001 北京同仁堂股份有限公司2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2026年1月16日 (二)股东会召开的地点：北京市东城区崇外大街42号同仁堂大厦5层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会由公司董事会召集，董事长张朝华女士主持。会议采用现场投票和网络投票相结合的表决方 式进行表决。会议的召集、召开和表决符合相关法律、法规及《北京同仁堂股份有限公司章程》的规 定。 (五)公司董事和董事会秘书的列席情况 1.公司在任董事11人，出席董事11人； 2.公司董事会秘书出席本次会议；部分高级管理人员列席本次会议。 二、议案审议情况 (一)非累积投票议案 表决情况： ■ 2.议案名称：《关于与关联方签订销售框架 ...

北 京 大 成 律 师 事 务 所 关 于 北 京 同 仁 堂 股 份 有 限 公 司 2026 年 第 一 次 临 时 股 东 会 的 法 律 意 见 书 大成证字[2026]第 005 号 北 京 大 成 律 师 事 务 所 www.dentons.cn 北京市朝阳区朝阳门南大街 10 号兆泰国际中心 B 座 16-21 层（100020） ZT International Center, No.10, Chaoyangmen Nandajie, Dongdaqiao Road Chaoyang District, 100020, Beijing, China Tel:+8610-58137799 Fax:+8610-58137788 1 北京大成律师事务所 关于北京同仁堂股份有限公司 2026 年第一次临时股东会的法律意见书 致：北京同仁堂股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他有关规范性文 件的要求，北京大成律师事务所（以下简 ...

一、 会议召开和出席情况 (一)股东会召开的时间：2026 年 1 月 16 日 (二)股东会召开的地点：北京市东城区崇外大街 42 号同仁堂大厦 5 层会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1. | 出席会议的股东和代理人人数 | 1,263 | | --- | --- | --- | | 2. | 出席会议的股东所持有表决权的股份总数（股） | 779,970,045 | | 3. | 出席会议的股东所持有表决权股份数占公司有表决权 | 56.8711 | | | 股份总数的比例（%） | | (四)表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 证券代码：600085 证券简称：同仁堂 公告编号：2026-001 北京同仁堂股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 本次股东会由公司董事会召集，董事长张朝华女士主持。会议采用现场投票 和网络投票相结合的表决方式进行 ...